List of Pemazyre drug patents
Pemazyre is owned by Incyte Corp.
Pemazyre contains Pemigatinib.
Pemazyre has a total of 3 drug patents out of which 0 drug patents have expired.
Pemazyre was authorised for market use on 17 April, 2020.
Pemazyre is available in tablet;oral dosage forms.
Pemazyre can be used as for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement, treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering once daily a tablet containing about 0.5 mg to about 10 mg of pemigatinib; treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib qd for 14 days then not administering pemigatinib for 7 days in a 21-day cycle; treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to about 20 mg.
Drug patent challenges can be filed against Pemazyre from 2024-04-17.
The generics of Pemazyre are possible to be released after 03 May, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9611267 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jan, 2035
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10131667 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jun, 2033
(10 years from now) | |
| US11466004 | INCYTE CORP | Solid forms of an FGFR inhibitor and processes for preparing the same |
May, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
| Orphan Drug Exclusivity (ODE) | Apr 17, 2027 |
| New Indication (I) | Aug 26, 2025 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 2024-04-17
Market Authorisation Date: 17 April, 2020
Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of p...
Dosage: TABLET;ORAL
PEMAZYRE family patents
15
United States
6
Japan
5
Israel
5
European Union
4
Australia
4
Lithuania
4
Hungary
4
Philippines
4
Argentina
4
Korea, Republic of
4
China
3
Denmark
3
Slovenia
3
Singapore
3
Croatia
3
Portugal
3
Spain
3
Peru
3
Poland
3
Chile
3
Taiwan, Province of China
3
RS
3
EA
3
Canada
3
New Zealand
2
Costa Rica
2
Colombia
2
Brazil
2
Cyprus
2
Malaysia
2
Ecuador
2
Ukraine
2
ME
1
IB
1
Mexico
1
Hong Kong
1
Morocco
1
Norway
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic